Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection

Creative Commons License

Pepeler M. S., YILDIZ Ş., YEGİN Z. A., ÖZKURT Z. N., GÜZEL TUNÇCAN Ö., ERBAŞ G., ...More

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, vol.12, no.9, pp.799-805, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 9
  • Publication Date: 2018
  • Doi Number: 10.3855/jidc.9961
  • Journal Name: JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.799-805
  • Keywords: invasive fungal infection, antifungal prophylaxis, voriconazole, amphotericin B, LIPOSOMAL AMPHOTERICIN-B, RISK-FACTORS, HEMATOLOGICAL MALIGNANCIES, MARROW-TRANSPLANTATION, ASPERGILLOSIS, DISEASES, VORICONAZOLE, EXPERIENCE, THERAPY, HISTORY
  • Gazi University Affiliated: Yes

Abstract

Introduction: Invasive fungal infection (IFI) is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. A previous history of IFI is not an absolute contraindication for allo-HSCT, particularly in the era of secondary antifungal prophylaxis (SAP). Prompt diagnosis and therapy are essential for HSCT outcome.